
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc has demonstrated strong performance in console sales for Q3, surpassing expectations even amidst delays in significant orders, indicating a robust demand for its innovative Tablo system. The company is effectively progressing towards profitability and achieving its financial goals, including a target of less than $50 million in cash burn for 2025, while its adjusted gross margin of 39.8% exceeded both consensus and internal guidance. The favorable market dynamics, including a growing Tablo pipeline and accelerated consumables ordering, along with under-penetrated market opportunities, further position Outset Medical for long-term growth and success in the dialysis sector.
Bears say
Outset Medical Inc. is facing challenges that have adversely impacted its financial outlook, as evidenced by a lowered full-year revenue guidance by approximately $7 million and disappointing quarterly performance. Consumables revenue, typically a strong point for the company, showed weakness due to reduced orders from acute care customers, contributing to total revenues falling short at $29.4 million compared to expected figures. Furthermore, factors such as delays in enterprise deal timelines, a significant console order postponed to Q4, and the departure of the head of sales are raising concerns about future revenue consistency and operational stability.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares